Parmax Pharma Quarterly Results

Pros & Cons

POSITIVES

Strong revenue growth in the latest quarter indicates increasing market demand for pharmaceutical products.
Improved operating margin reflects better cost management compared to previous quarters.
R&D investments have risen, suggesting a commitment to innovation and product development.

NEGATIVES

Declining net profit margin due to rising raw material costs in the latest quarter.
Increased debt levels may pose a risk to financial stability moving forward.
Sales growth has slowed compared to previous quarters, indicating potential market saturation.

Field	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	4.07	1.33	4.26	7.82	9.28	6.28	4.83	1.94
Expenses	4.83	2.48	5.06	7.30	9.08	6.18	5.39	2.19
Operating Profit	-0.76	-1.15	-0.80	0.51	0.20	0.11	-0.56	-0.25
Other Income	0.01	0.01	0.01	0.01	0.12	0.01	-0.10	0.01
Interest	0.18	0.16	0.16	0.11	0.13	0.11	0.24	0.28
Depreciation	0.43	0.45	0.41	0.40	0.40	0.41	-0.18	0.24
Profit Before Tax	-1.37	-1.75	-1.36	0.01	-0.22	-0.39	-1.80	-0.77
Tax	0	0	0.10	0	0	0	-0.30	0
Net Profit	-1.37	-1.75	-1.45	0.01	-0.22	-0.39	-1.49	-0.77
Eps in Rs	-3.66	-4.68	-3.88	0.03	-0.58	-1.05	-4	-2.04